Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity

Content Provider	Semantic Scholar
Author	Laskey, Robin A. Richard, Scott D. Smith, Ashlee L. Lin, Jeff F. Beck, Tiffany Lesnock, Jamie L. Kelley, Joseph Leo Olawaiye, Alexander Babatunde Sukumvanich, Paniti Krivak, Thomas C.
Copyright Year	2014
Abstract	PURPOSE Bevacizumab (Bev) is associated with improved progression-free survival in advanced epithelial ovarian cancer. The use of Bev in patients with gynecologic malignancy is increasing; however, little is known about cumulative toxicity and response in patients retreated with Bev. Our goal was to determine cumulative side effects and response in patients retreated with Bev. PATIENTS AND METHODS Women with recurrent gynecologic malignancy treated with Bev between January 2007 and March 2012 at a single institution were identified, including a subset who received Bev in a subsequent regimen. The primary outcome was Bev-associated toxicity, and the secondary outcome was response. RESULTS Of 83 patients that received Bev for recurrent disease, 23 were retreated with Bev and four received Bev maintenance. Three patients (13%) developed grade 3 or 4 hypertension; all had a history of chronic hypertension. One (4.3%) patient developed grade 3 proteinuria, and one (4.3%) developed an enterovaginal fistula. Four patients discontinued Bev secondary to toxicity. Toxicity was not related to the cumulative number of cycles. Twenty-six percent of patients responded to Bev retreatment. On univariate analysis, there was a significant (P=0.003) overall survival advantage when the Bev-free interval was >9 months (95% confidence interval [CI] 4.9-43.7) compared to ≤9 months (95% CI 2.1-11.5), 24.3 months, and 6.8 months. CONCLUSION Retreatment of patients with recurrent gynecologic malignancy with Bev did not increase morbidity and was associated with treatment response. Physicians treating women with recurrent disease may consider a Bev-containing regimen even if prior regimen(s) included Bev. Future studies should prospectively evaluate the efficacy of this treatment strategy.
Starting Page	469
Ending Page	476
Page Count	8
File Format	PDF HTM / HTML
DOI	10.2147/OTT.S57425
Alternate Webpage(s)	https://www.dovepress.com/getfile.php?fileID=19377
Alternate Webpage(s)	http://ftp.ncbi.nlm.nih.gov/pub/pmc/be/ed/ott-7-469.PMC3968081.pdf
Alternate Webpage(s)	https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/ed/ott-7-469.PMC3968081.pdf
PubMed reference number	24711703
Alternate Webpage(s)	https://doi.org/10.2147/OTT.S57425
Journal	Medline
Volume Number	7
Journal	OncoTargets and therapy
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article